|

Albumin-Bound Paclitaxel Clinical Trials

16 actively recruiting trials across 1 location

Also known as: Abraxane®, Nab-Paclitaxel, Paclitaxel, albumin paclitaxel, gemcitabine

Pipeline

Phase 2: 5Phase 3: 3Phase 4: 1Phase 1/2: 6

Top Sponsors

  • Chinese PLA General Hospital2
  • Tianjin Medical University Cancer Institute and Hospital1
  • The First Affiliated Hospital of Bengbu Medical University1
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1
  • Tang-Du Hospital1

Indications

  • Cancer16
  • Pancreatic Cancer2
  • Gastric Cancer2
  • Lung Cancer2
  • Breast Cancer2

Other15 trials

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Phase 1/2
AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Phase 2
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
Phase 2
Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
Phase 4
Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma
Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
Phase 1/2
Chemoradiotherapy in Unresectable Esophageal Cancer
Phase 1/2
HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
Phase 1/2
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
Phase 1/2
Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC
Phase 2
Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
Phase 2
Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial
Phase 3
Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）
Phase 3
Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors
Phase 1/2
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
Phase 2

Phoenix, Arizona1 trial

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Mayo Clinic

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.